Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Buprenorphine: A Simple, Step‑by‑Step Journey Through the Body
Mohamad-Ali Salloum, PharmD • March 7, 2026
Share
Pharmacology
PK/PD
Buprenorphine: A Simple, Step‑by‑Step Journey Through the Body
A clear guide for pharmacy students learning PK/PD the smart way. Short chunks. Visual cues. A quick quiz at the end.
Strong grip
= high MOR affinity
Weak push
= partial agonism
1) Quick History
Where Buprenorphine Came From
Developed in the late 1960s from thebaine(a poppy plant derivative), buprenorphine was designed to give useful opioid effects with a safer profile. It binds very strongly to μ‑opioid receptors (MORs) but only partially activates them.
Opioid Use Disorder (OUD)
Chronic Pain (select cases)
2) The Patient
Why Buprenorphine Is Needed
Classic opioid withdrawal may include: runny nose, yawning, dilated pupils, goosebumps, stomach cramps, anxiety, and fast heartbeat — all due to under‑stimulation of MORs.
⚠️
Critical rule:
Start buprenorphine only when moderate withdrawal
is present. If given too early, it can displace a full agonist and cause precipitated withdrawal.
3) Absorption
How Buprenorphine Enters the Body
Sublingual is the most common route because swallowing leads to extensive first‑pass metabolism. Under the tongue, it reaches systemic circulation directly.
Bioavailability
~30–50% (sublingual)
T max
1–4 hours
Protein binding
~96%
Half‑life
~24–37 hours
Naloxone in combo products has minimal sublingual absorption; it mainly matters if injected.
Hover the button to simulate absorption
4) Distribution
Where the Drug Travels
- Crosses the blood–brain barrier(high lipophilicity)
- Accumulates in fat — slow release over time
- Highly protein‑bound(~96%)
- Crosses the placenta and appears in breast milk
Memory hook: “Couch‑potato molecule”
— likes fat, stays longer.
5) Pharmacodynamics
What the Drug Does
MOR: Partial agonist
KOR: Antagonist
DOR: Antagonist/weak partial agonist
ORL‑1: Partial agonist
Show intracellular actions
- ↓ cAMP
- ↓ presynaptic Ca²⁺ → ↓ pain neurotransmitter release
- ↑ K⁺ efflux → hyperpolarization
✅
Clinical effects:
reduces withdrawal and cravings, provides analgesia, ceiling effect on respiratory depression
, and functionally blocks other opioids (very high MOR affinity). PET studies suggest ~ 70% MOR occupancy
helps suppress withdrawal and block opioid effects.
6) Metabolism
How the Body Breaks It Down
- Phase I – CYP3A4: buprenorphine → norbuprenorphine (active, poor CNS entry)
- Phase II – UGT1A1 & UGT2B7: glucuronidation → water‑soluble metabolites
Memory line:
“3A4 cuts, UGTs clean.”
CYP3A4 inhibitors ↑ levels
CYP3A4 inducers ↓ levels
Liver disease: adjust
Kidney disease: modest effect
7) Elimination
How It Leaves the Body
- ~70% via feces (major)
- ~30% via urine (mostly metabolites)
- Some enterohepatic recirculation
8) A → Z Story
One‑Glance Journey (Sublingual Dose)
A.
Patient arrives in moderate withdrawal.
B.
Sublingual film dissolves → absorbed through oral mucosa.
C.
Avoids first‑pass metabolism → enters systemic circulation.
D.
Travels in blood (mostly protein‑bound).
E.
Free drug crosses into the brain.
F.
Strong MOR binding → partial
activation.
G.
Withdrawal/cravings decrease; ceiling effect improves safety.
H.
Liver enzymes break it down (CYP3A4 + UGTs).
I.
Metabolites go to bile and kidneys.
Z.
Excreted in feces (major) and urine (minor).
9) Key Clinical Tips
High‑Yield for Students
- Start only in moderate withdrawal to avoid precipitated withdrawal.
- Typical OUD maintenance: 12–16 mg/day (individualize per labeling/clinical response).
- Watch CYP3A4 interactions(inhibitors ↑ levels; inducers ↓ levels).
- CNS depressants increase respiratory risk despite the ceiling.
- Acute pain is trickier due to receptor blockade — use multimodal strategies.
Check Yourself
Quick Quiz: Can You Recall the Essentials?
1) Why is sublingual buprenorphine preferred over oral swallowing?
2) The best time to start buprenorphine is:
3) Which statement is correct?
4) Main elimination route?
5) Quick metabolism memory aid:
References :
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw‑Hill; 2018.
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang & Dale’s Pharmacology. 9th ed. Elsevier; 2020.
- Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59‑S77.
- SAMHSA. TIP 63: Medications for Opioid Use Disorder. Rockville, MD; 2018.
- Suboxone® (buprenorphine/naloxone) sublingual film. U.S. Prescribing Information. Indivior.
- Kuhlman JJ Jr, et al. Human pharmacokinetics of sublingual buprenorphine. J Anal Toxicol. 1996;20(6):369‑378.
- Rouguieg‑Malki K, et al. Contribution of UGTs and CYP3A4 to buprenorphine metabolism. Drug Metab Dispos. 2011;39(12):2059‑2066.
- Dahan A, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627‑632.
- Greenwald MK, et al. Buprenorphine dose, MOR occupancy, and blockade of opioid effects. Neuropsychopharmacology. 2003;28(11):2000‑2009.
- Lund IO, et al. Pregnancy outcomes on buprenorphine vs methadone. Addiction. 2013;108(2):255‑262.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
Explore the difference between Sensitivity and Specificity
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to Distinguish Correlation from Causation in Orthopaedic Research. J Arthroplasty. 2022;38(4):634‑637. [pmc.ncbi.nlm.nih.gov] Association of Health Care Journalists. Correlation vs. Causation. [healthjournalism.org] Rush J, Ajami M, Look K, Margolis A. Statistics Review Part 10: Causality and Confounding. J Pharm Soc Wis. [jpswi.org] Biostat Prime. Correlation vs Causation: Meaning, Differences & Examples. [biostatprime.com] Koopmans E, Schiller C. Understanding Causation in Healthcare: An Introduction to Critical Realism. Qual Health Res. 2022;32(8–9):1207–1214. [pmc.ncbi.nlm.nih.gov]
References: Very Big Brain. Somatic Memories: How Physical Sensations Trigger Past Memories and Emotions . 2023 Nov 26. [verybigbrain.com] Misattribution of arousal. Wikipedia . 2026. [en.wikipedia.org] Zimbardo P. The Misattribution of Arousal Study (Dutton & Aron) . 2026. [zimbardo.com] Higgins L. Why You Feel Anxious After Drinking Coffee . TIME. 2025 Nov 11. [time.com] Double KS. Metacognitive ability is associated with reduced emotion suppression . Scientific Reports. 2026 Jan 28. [nature.com] Merkebu J et al. What is metacognitive reflection? Front Educ. 2023 Apr 5. [researchgate.net] Meyers S et al. Cognitive Reappraisal is More Effective for Regulating Emotions than Moods . Affective Science. 2025 Jun 6. [link.springer.com]
Are they the same?
A Practical Guide for the Public.
Did you know that your emotions are just suggestions?
Short-form videos like Reels and TikTok rapidly trigger dopamine, stress, and attention circuits—discover how they impact your brain, mood, and focus, plus practical tips to restore balance.